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Background: Hepatocellular carcinoma (HCC) is a malignancy with poor survival outcome. New treatment options
for the disease are needed. In this study, we identified and evaluated tumor vascular PLVAP as a therapeutic target
for treatment of HCC.
Methods: Genes showing extreme differential expression between paired human HCC and adjacent non-tumorous
liver tissue were investigated. PLVAP was identified as one of such genes with potential to serve as a therapeutic
target for treatment of HCC. A recombinant monoclonal anti-PLVAP Fab fragment co-expressing extracellular domain
of human tissue factor (TF) was developed. The potential therapeutic effect and toxicity to treat HCC were studied
using a Hep3B HCC xenograft model in SCID mice.
Results: PLVAP was identified as a gene specifically expressed in vascular endothelial cells of HCC but not in non-
tumorous liver tissues. This finding was confirmed by RT-PCR analysis of micro-dissected cells and immunohistochemical
staining of tissue sections. Infusion of recombinant monoclonal anti-PLVAP Fab-TF into the main tumor feeding artery
induced tumor vascular thrombosis and extensive tumor necrosis at doses between 2.5 μg and 12 μg. Tumor growth
was suppressed for 40 days after a single treatment. Systemic administration did not induce tumor necrosis. Little
systemic toxicity was noted for this therapeutic agent.
Conclusions: The results of this study suggest that anti-PLVAP Fab-TF may be used to treat HCC cases for which
transcatheter arterial chemoembolization (TACE) is currently used and potentially avoid the drawback of high viscosity of
chemoembolic emulsion for TACE to improve therapeutic outcome. Anti-PLVAP Fab-TF may become a viable therapeutic
agent in patients with advanced disease and compromised liver function.
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Worldwide, primary liver cancer is the fifth most com-
mon cancer in men and the seventh in women. An esti-
mated 748,300 new liver cancer cases occurred during
2008 [1]. Approximately 695,500 people died from liver
cancer that same year. Globally, HCC is the second lead-
ing cause of cancer death in men and the sixth leading
cause among women. HCC accounts for 85% of primary
liver cancer [2] and is endemic in Southeast Asia and
Sub-Saharan Africa. Although HCC is uncommon in* Correspondence: kjkao@kfsyscc.org
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unless otherwise stated.western countries, incidence of the disease increased
two fold between 1985 and 1998 and is expected to in-
crease until 2020 in the United States [3]. Despite its
relatively low incidence, HCC is the fifth and the ninth
leading cause of cancer deaths for men and women, re-
spectively, in the US [4]. The five year overall survival
rate for patients with HCC is only 15% [5].
Early stage solitary HCC can be treated with surgical re-
section, ablative intervention (radiofrequency ablation and
ethanol injection) or liver transplantation. Intermediate
stage HCC can be treated with transcatheter arterial
embolization (TAE) or chemoembolization (TACE). Treat-
ment using TACE has been shown to prolong survival [6].
However, this treatment approach has drawbacks. TACEtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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emulsified in lipiodol oil) evenly and thoroughly in tumors,
particularly larger tumors due to high viscosity of che-
moembolic emulsion [7]. The infused embolization parti-
cles (e.g. Ivalon™, Gelfoam) and chemotherapeutic agents
also can damage hepatic arteries, cause blood vessel occlu-
sion, and prevent patients from receiving further TAE or
TACE treatment for recurrent disease. The newer radiola-
beled microspheres are effective to control disease proger-
ession but associated with radiation-induced injury to liver,
lung and gastrointestinal tract [8-10]. HCC patients with
liver cirrhosis and impaired liver function are often pre-
cluded from treatment using cytotoxic chemotherapeutic
agents [11,12]. Although targeted therapy with sorafenib is
beneficial for some patients through probable disruption of
tumor angiogenesis, the effectiveness of the treatment has
been modest [13]. Further improvement in treatment of
HCC patients with intermediate and advanced stage dis-
ease is urgently needed.
Through a comparative study of gene expression in
paired tumor and adjacent non-tumorous tissues, we
discovered that PLVAP protein was specifically expressed
in vascular endothelial cells of HCC and not in vascular
endothelial cells of non-tumorous liver tissue. This dif-
ferential expression of PLVAP provides a potential target
for HCC treatment. We therefore developed a recom-
binant monoclonal anti-PLVAP Fab fragment that co-
expresses a water-soluble extracellular domain of human
tissue factor (anti-PLVAP Fab-TF), which was shown ef-
fective to treat HCC in a Hep3B xenograft model using
SCID mice.
Methods
Animal use and human subject
The use of small vertebrate animals was approved by the
Koo Foundation Sun Yat-Sen Cancer Center Institutional
Animal Care and Use Committee (ID number 20100908-
1). The de-identified gene-expression dataset and the de-
identified paraffin tissue blocks with histological diagnosis
of HCC were obtained from the central institutional
depository and used in the present study. The study was
approved and granted exemption of informed consent by
the Koo Foundation Sun Yat-Sen Cancer Center Institu-
tional Review Board (ID number 20060731A).
Identification of differentially expressed genes in HCC
Gene expression profiles of eighteen pairs of frozen fresh
HCC and adjacent non-tumorous liver tissues were
determined using the Affymetrix GeneChip Human
Genome U133A array as reported [14]. The tissues used
in this dataset were collected from surgically excised
liver for treatment of HCC. Genes that showed extreme
differential expression between paired HCC and adjacent
non-tumorous liver tissues were identified by followingthe steps described below. Affymetrix MAS5.0 and
dChip (version 2004) softwares were both used to define
expression status of each gene as ‘present’, ‘absent’ or
‘marginal’ in all 18 pairs of tissues. Tumor-specific genes
showing extreme differential expression were defined as
genes classified as ‘present’ by both MAS 5.0 and dChip
softwares in HCC tissue and ‘absent or marginal’ in the
paired adjacent non-tumorous liver in at least 16 out of
18 pairs of these tissues. By adopting such an approach,
we identified two tumor-specific genes that showed ex-
treme differential expression between HCC and adjacent
non-tumorous liver tissue. One was PLVAP and the
other was MELK. The microarray dataset has been de-
posited at the Gene Expression Omnibus under acces-
sion number GSE60502.
Laser capture microdissection
Laser capture micro-dissection (LCM) of formalin fixed
HCC tissue sections was carried out using the Arcturus
PixCellR IIe system, CapSure™ HS LCM caps, and the
Paradise™ reagent system from Arcturus Bioscience, Inc.
(Mountain View, CA). First, seven micrometer thick tis-
sue sections were de-paraffinized, rehydrated, and stained
for LCM according to the manufacturer’s instructions.
Target cells were captured on CapSure™ HS LCM caps
using a 7.5-μm spot-size laser set at 50 mW power and
1.3 ms duration. Approximately 5000 to 6000 HCC cells
without vascular endothelium or adjacent non-tumorous
liver were captured on each cap and prepared for RNA ex-
traction. Additionally, vascular endothelial cells were care-
fully dissected from the HCC tissue. Only 1000 to 2000
HCC vascular endothelial cells were captured for RNA ex-
traction due to their relative paucity.
RNA extraction and real time quantitative RT-PCR for
PLVAP mRNA
Cells captured on LCM caps were used for RNA extrac-
tion, cDNA synthesis, in vitro transcription and anti-
sense RNA amplification using the Paradise™ reagent
system in accordance with the manufacturer’s instructions.
The first reverse transcription step was carried out using
4.5 μl anti-sense RNA and TaqMan Reverse Transcription
Reagents (Applied Biosystems, Carlsbad, California) in a
final volume of 10 μl according to the manufacturer’s
protocol. The second step of real-time PCR was performed
using 2.4 μl of cDNA template, TaqMan primers/probe
mix and universal PCR Master Mix (Applied Biosystems)
in a final volume of 25 μl. Real-time PCR was performed
using a Smart Cycler II (Cephid, Inc., Sunnyvale, CA). Re-
actions were initially incubated at 50°C for 2 minutes and
then at 95°C for 10 minutes. Thereafter, there were 45 cy-
cles of denaturation at 95°C for 15 seconds and annealing/
extension at 60°C for 40 seconds. The primer and probe
sequences are listed in (Additional file 1: Table S1).
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A murine anti-human PLVAP monoclonal antibody (GY5
mAb), which was developed in-house, was used to study
PLVAP expression in HCC and non-tumorous liver tissue.
This mAb binds to a linear antigenic epitope correspond-
ing to amino acids 331 to 441 of human PLVAP protein.
To study murine PLVAP expression using Hep3B tumor
xenografts, rat anti-mouse PLVAP mAb prepared from
MECA32 hybridoma supernatant was used [15]. This hy-
bridoma was obtained from the Developmental Studies
Hybridoma Bank at the University of Iowa (Iowa City, IA).
Immunohistochemical staining was performed using a
Benchmark XT automated stainer (Ventana Medical
Systems, Inc., Tucson, AZ). After antigen retrieval and
blocking of endogenous peroxidase, tissue sections were
incubated with 1 μg/ml anti-human or 5 μg/ml anti-mouse
PLVAP monoclonal antibody at 37°C for 48 minutes. The
sections were then processed using the iView™ DAB Detec-
tion Kit (Ventana Medical Systems). When performing
IHC using rat anti-mouse mAb, biotinylated rabbit
anti-rat IgG (AbD Serotec, Oxford, UK) was used to re-
place the biotinylated second antibodies in the iView™
DAB Detection Kit.Establishing Hep3B xenografts in SCID mice
To establish a HCC xenograft model in BALB/c C.B-17
SCID mice, 4 million Hep3B cells were subcutaneously
injected at the right inner thigh of SCID mice. Hep3B cells
were cultured in DMEM media containing 10% fetal bo-
vine serum, 1% GlutaMax™, 1x antibiotic-antimycotic and
10 mM HEPES. All cell culture reagents were purchased
from Life Technologies (Grand Island, NY). Cells were
treated with EDTA solution (Life Technologies) and
harvested upon reaching 80% confluence. After being
washed with serum-free DMEM, Hep3B cells were sus-
pended in ice cold serum-free DMEM containing 75%
Matrigel (BD Biosciences, San Jose, CA) at a concentra-
tion of 66.7 million cells per milliliter. After subcutane-
ous injection of four million Hep3B cells suspended in
Matrigel, it took the injected tumor cells 5 to 6 weeks
to grow and become ready for study. Initially, tumor
sizes were manually monitored each week using an
electronic caliper. Later, a Vevo 2100 3D Ultrasound
Imaging System (Visual Sonics, Toronto, Canada) was
used. Blood flow in Hep3B tumors was assessed by 3D
power Doppler using the same ultrasound imaging sys-
tem. To compare blood flow before and after treatment,
the same parameters were used for sonography and
power Doppler before and after treatment in the same
experiment. To reduce background noise further, the
sensitivity setting used for power Doppler experiment
of Figure 1 was lower than that used in the experiment
of Figure 2.Chemical conjugation of recombinant GST-hTF to MECA32
rat anti-mouse PLVAP mAb
Purified MECA32 mAb was dialyzed in 0.1 M 2-(N-
morpholino) ethanesulfonic acid (MES) buffer containing
0.5 M NaCl at pH 6.0. The antibody was adjusted to 1 mg/
ml. Additionally, 1 ml of MECA32 mAb, 1.2 mg EDC (1-
Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochlor-
ide) and 3.3 mg of sulfo-NHS (N-hydroxysulfosuccinimide)
were added. After gentle vortexing to dissolve the added
reagents, the mixture was incubated at room temperature
for one hour. A Zeba desalting column (Thermo Fisher
Scientific Inc., Rockford, IL) pre-equilibrated with PBS
coupling buffer was used to recover activated MECA32
mAb. Next, an equal mole of GST-hTF (0.33 mg in
0.66 ml) was added to the activated MECA32-mAb. The
mixture was incubated on a rotary mixer for 3 hours at
room temperature. The reaction was then quenched by
adding hydroxylamine to a final concentration of 10 mM.
The antibody conjugated with human tissue factor protein
was extensively dialyzed against 1x phosphate buffered sa-
line. The concentration of antibody was determined by ab-
sorbance at 280 nm using an extinction coefficient of 1.37
for 1 mg/ml. The antibody conjugated with human tissue
factor (MECA32-TF) was characterized for its tissue factor
activity using a chromogenic substrate assay [16], and for
binding to mouse PLVAP using an ELISA assay (Additional
file 2: Supplementary Methods). The production of water
soluble and truncated forms of GST-hTF and mouse
PLVAP proteins is detailed in the Supplementary Methods.
Production of a recombinant anti-mouse PLVAP Fab
fragment co-expressing hTF
To produce a therapeutic biologic with a well-defined
structure and stoichiometry between anti-PLVAP mAb
and hTF, a recombinant anti-murine PLVAP Fab frag-
ment co-expressing hTF at the carboxyl terminus of the
Fd chain was developed. The Fab fragment of this thera-
peutic biologic was derived from MECA32 mAb. The
procedures for preparation of MECA32 anti-PLVAP Fab-
TF recombinant protein (MECA32-Fab-TF) are detailed
in the Additional file 2. The purified MECA32-Fab-TF
was analyzed using SDS-PAGE and characterized for
PLVAP binding activity and human tissue specific activity
before use.
Arterial infusion for treatment in Hep3B tumor xenografts
To demonstrate the therapeutic effect of MECA32-TF
and MECA32-Fab-TF on Hep3B xenografts, different
doses of MECA32-TF or MECA32-Fab-TF were infused
into the main tumor feeding femoral artery. Mice carrying
Hep3B tumor xenografts were anesthetized by isoflurane
(Baxter, Guayana, Puerto Rico) inhalation and laid in the
supine position under a dissecting microscope. The hair
over the right inguinal area was removed with Nair™ hair
Figure 1 Changes of tumor blood flow and tumor histology at 2, 4, 24, 48 and 72 hours after treatment with 10 μg MECA32-Fab-TF.
Tumor blood flow was monitored using 3D power Doppler sonography (upper panel). The histology sections were stained with hematoxylin and
eosin (lower panel). There were two mice at each time point. Results were the same between two mice at each time point. Only result from one
of the two mice studied at each time point is shown. Upper panel shows change of tumor blood flow before and after treatment. White arrows
point at blood flow signal in tumors. Blood flow signal disappeared at 2 hours and persisted up to 72 hours. Lower panel shows that fibrin thrombi (balck
arrows) in blood vessels became evident at 2 hours after treatment and persisted throughout the study period. Tumor tissue became morphologically
degenerated at 24 hours. Frank necrosis became evident at 48 hours. Photomicrographs were taken at 100x magnification.
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before infusion. After cleansing the skin with 75% alcohol,
a 0.5-cm incision was made at the right inguinal area just
above the tumor. The right femoral artery and vein were
exposed, and the femoral artery was then looped with a
6-0 nylon thread. The artery was gently retracted proxim-
ally. An arteriotomy was performed using a micro-scissor
distal to the retraction and a fine 33-gauge needle was
inserted into the vascular lumen. MECA32-TF, MECA32-Fab-TF or control MECA32 antibody was infused at a
rate of approximately 40 μl per minute. Injection was
performed under a dissecting microscope to ensure that
there was no leakage. After infusion, the needle was
withdrawn and the arteriotomy site was sealed with
Histoacryl (TissueSeal, Ann Arbor, MI). The nylon for
retraction was removed. After confirmation of adequate
hemostasis, the incision was closed using a continuous
suture.
AB
Figure 2 Blood supply and tumor growth in Hep3B tumor xenografts after intra-arterial infusion of 20 μg MECA32 mAb chemically
conjugated with human tissue factor (MECA32-TF) into a tumor feeding femoral artery. Control mice were infused with 20 μg MECA32
mAB. A: Power Doppler was performed 48 hours before and after the treatment. Red signals in tumors represent blood flow, which were
significantly diminished in mice after treating with MECA32-TF (white arrow) but not in those treated with control MECA32 mAb. B: Tumor
growth before and after treatment. Solid circles (•) are control mice and crosses (x) are mice treated with MECA32-TF. †: Death.
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All statistical analyses were carried out using the R soft-
ware package (v2.6) from Bioconductor (http://www.bio-
conductor.org). Descriptive statistics, analysis of variance,
and linear mixed-effect model analysis [17] were used to
analyze results obtained from different experiments as
indicated.
Results
Identification of PLVAP as a therapeutic target for HCC
To identify genes specifically expressed in HCC and not
in non-tumorous liver tissue, we compared the gene ex-
pression profiles of 18 pairs of HCC and adjacent non-
tumorous liver tissues. HCC-specific gene expression
was defined as expression of a gene determined to be
“present” in HCC and “absent or marginal” in adjacent
non-tumorous liver tissues by both MAS5.0 and dChip
softwares in at least 16 of the 18 pairs of tissue samples.
Using this stringent approach only two genes met thecriteria. One was PVLAP and the other was MELK.
After further examining PLVAP expression in all 18 tis-
sue pairs (Figure 3A), we found that all pairs but one
showed higher PLVAP expression in the HCC tissues.
The differential expression of PLVAP in HCC was con-
firmed in 16 out of the same 18 tissue pairs using
TaqMan real time quantitative RT-PCR (Figure 3B).
PLVAP is a known structural protein of the endothelial
stomatal and fenestral diaphragms and is found in special-
ized vascular endothelial cells [18,19]. To confirm that
PLVAP expression in HCC tissue was indeed confined to
vascular endothelial cells, laser capture micro-dissection
was used to harvest tumor vascular endothelial cells and
tumor cells from two different cases of formalin-fixed
paraffin-embedded HCC tissue blocks (Additional file 1:
Figure S1). We also dissected adjacent non-tumorous
liver cells and sinusoid-lining endothelial cells (Additional
file 1: Figure S1). RNA extracted from the dissected cells
was analyzed for PLVAP gene expression using TaqMan
Figure 3 Differential expression of PLVAP between paired HCC tissue and adjacent non-tumorous liver tissue. A: Differential expression
of the PLVAP gene according to microarrays of 18 pairs of HCC and adjacent non-tumorous liver tissue. PN: paired non-tumorous liver; PHCC:
paired HCC tissue. B: Relative quantities of PLVAP mRNA in the same 18 tissue pairs. One non-tumorous liver tissue sample was chosen as a
reference control (relative quantitative expression = 1). C: Immunohistochemical (IHC) staining of PLVAP in four randomly selected HCC cases. IHC
staining was performed using GY5 murine anti-human PLVAP monoclonal antibody. Endothelial cells lining blood vessels of HCC showed positive
staining for PLVAP in brown color (arrows). IHC staining (panel C) showed that PLVAP was not expressed by the endothelial cells of hepatic
central vein (C-II right panel), hepatic sinusoid (CI-IV right panels), and hepatic arterioles (portal tract) (C-III right panel) in the adjacent non-
tumorouse liver tissues. The large empty space in the right panel of C-II was lumen of a hepatic central vein which showed absence of PLVAP
expression in the lining endothelial cells. We also stained HCC sections including adjacent non-tumorous liver with anti-human CD34 monoclonal
antibody. Endothelial cells of hepatic central vein and hepatic areteriole were stained positively for CD34 expression (data not shown). Liver sinusoidal
endothelial cells did not express CD34 as expected.
Table 1 Quantification of PLVAP mRNA in HCC vascular
endothelial cells, HCC tumor cells and adjacent non-
tumorous liver tissue using laser-capture microdissection
and Taqman real time quantitative RT-PCR












I 100% 0.2% 0%
II 100% 0.60% 0.1%
The tracings of Taqman real time quantitative RT-PCR are shown in Additional
file 1: Figure S1.
Two randomly selected HCC samples were studied.
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PLVAP gene expression in HCC tissue was restricted to
tumor vascular endothelial cells (Table 1 and Additional
file 1: Figure S2). HCC tumor cells and non-tumorous
liver tissues did not express significant amount of PLVAP.
The specific expression of PLVAP by tumor vascular
endothelial cells was further confirmed by immunohisto-
chemical staining using monoclonal anti-human PLVAP
antibodies (Figure 3C). We found that PLVAP is
expressed in vascular endothelial cells of HCC but not
in the endothelial cells of the liver sinusoid, central vein,
portal vein or hepatic arteriole (Figure 3C). PLVAP ex-
pression was not detected in vascular endothelial cells of
the metastatic colon or ovarian cancer in the liver (data
not shown). PLVAP was neither detected in vascular
endothelial cells taken from focal nodular hyperplasia of
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ferentially expressed in vascular endothelial cells of HCC.
Therefore, PLVAP could serve as a useful therapeutic tar-
get for treatment of HCC. Using immunohistochemical
staining, we also found that endothelial cells of mouse
blood vessels grown in a Hep3B xenograft expressed mur-
ine PLVAP (Additional file 1: Figure S3).
Targeting PLVAP to treat HCC xenografts using MECA32-TF
To determine whether PLVAP expression in tumor vas-
cular endothelial cells could be used as a target for treat-
ing Hep3B xenograft, monoclonal MECA32 anti-PLVAP
antibody was chemically cross-linked with the extrace-
llular domain of human tissue factor (MECA32-TF).
Tissue factor is a potent trigger of blood coagulation
protein [20,21]. The prepared MECA32-TF had 385 μg
TF activity per mg of conjugated antibody. Each SCID
mouse bearing a Hep3B tumor xenograft was infused
with 20 μg MECA32-TF into a tumor feeding artery.
The control group was treated with 20 μg MECA32
mAb. The effect on tumor blood flow and growth before
and after infusion was monitored using 3D power Dop-
pler sonography. The results demonstrated that infusion
of 20 μg MECA32-TF led to tumor blood flow blockage
(Figure 2A) and suppressed tumor growth (Figure 2B).
In contrast, there was no blockage of tumor blood sup-
ply or growth in the control group (Figure 2).
Production and characterization of recombinant
MECA32-Fab-TF
Although MECA32-TF prepared by chemical conjuga-
tion was therapeutically active, SDS-PAGE indicated that
the number of TF protein molecules cross-linked to each
MECA32 mAb was heterogeneous. To create a thera-
peutic anti-PLVAP antibody with a well-defined structure
and a lower molecular weight to shorten circulation half-
life and limit potential adverse effects, we developed a
recombinant monoclonal MECA32 Fab fragment co-
expressing the extracellular domain of human tissue factor
protein at the carboxyl end of the Fd fragment (MECA32-
Fab-TF) (Additional file 1: Figure S4). This recombinant
Fab-TF had a molecular weight of 81 kDa. Based on six
different batches of MECA32-Fab-TF, the average tissue
factor specific activity was 90 ± 22 μg (mean ± SD) in each
mg of MECA32-Fab-TF and the average binding affinity to
recombinant PLVAP protein (Kd) was 5.7 ± 1.4 × 10−8 M
(mean ± SD) using a steady state binding assay and Scatch-
ard analysis (Additional file 2).
Effect of anti-PLVAP MECA32-Fab-TF on Hep3B tumor
xenografts within 72 hours of treatment
SCID mice bearing human Hep3B tumor xenografts at
the right inner thigh were infused with 10 μg MECA32-
Fab-TF into the main tumor feeding femoral artery undera dissecting microscope. The treated SCID mice were
sacrificed at 0, 2, 4, 24, 48 and 72 hours after treatment.
There were two mice at each time point. Power Doppler
was used to monitor tumor blood flow before and after
treatment. Necropsy was performed and tumors were har-
vested for histological examination. The results of power
Doppler imaging showed tumor blood flow blockage at
2 hours after treatment, and this effect persisted through-
out the 72-hour study period (Figure 1). Histological
examination of the tumors indicated that thrombi with
fibrin-like deposits were discernible in tumor blood vessels
2 hours after infusion. Blood vessels with thrombi present
in tumor capillaries and venules became more prominent
at four and twenty four hours after treatment. At 24 hours,
tumor cells began to show loss of cohesiveness. At 48 hours,
frank ischemic necrosis became evident. The textbook
histological criteria were used to assess necrosis [22]. These
findings as shown in Figure 1 suggest that infusion of anti-
PLVAP MECA32-Fab-TF into the main tumor feeding
artery triggered thrombosis in tumor blood vessels, blocked
tumor blood flow and caused ischemic necrosis of tumors.
We did not find any bleeding at the incision site in any of
the treated mice. No gross adverse systemic effects were
noted.
Next, we studied tumor necrosis induced by different
doses of MECA32-Fab-TF in two separate experiments.
Tumor necrosis was assessed 72 hours after treatment.
As shown in Figure 4, a dose as low as 2.5 to 3 μg was suf-
ficient to induce 68% to nearly 100% necrosis in tumor xe-
nografts. The results of these two studies indicated that
infusion of 10 μg MECA32-Fab-TF could more consist-
ently induce near total necrosis of tumors with an average
size approximately 0.2 ml (Figure 4).
Effect of anti-PLVAP MECA32-Fab-TF on growth in Hep3B
tumor xenografts
We then studied the effect of MECA32-Fab-TF treatment
on tumor growth. Two different studies were conducted.
The first study followed tumor growth for 25 days after
treatment, at which point the tumors in the control group
grew too large and the study was stopped. Tumor growth
was monitored using 3D sonography. SCID mice bearing
Hep3B xenografts were treated with 5 μg or 10 μg of
MECA32-FAb-TF and controls were treated with 10 μg of
MECA32 mAb without tissue factor. The results, shown
in Figure 5A, demonstrate that a single dose of 5 μg or
10 μg MECA32-Fab-TF effectively suppressed tumor
growth; this effect was not observed in mice given 10 μg
MECA32 mAb as a control. Power Doppler study again
revealed significant reduction of tumor blood flow 2 hours
after treatment with MECA32-Fab-TF, but not in control
mice treated with MECA32 mAb.
In the second study, SCID mice bearing Hep3B tumor
xenografts were treated with intra-arterial infusion of 10 μg
Figure 4 Tumor necrosis 72 hours after infusion of different doses of MECA32-Fab-TF. The results of two different studies are shown here.
The largest tumor cross sections were submitted for histology and studied. Necrotic tumors and viable residual tumors were outlined as areas of
pink and blue, respectively. The relative size of necrotic and viable tumor tissue was measured based on two dimensional areas. Percentages
shown in the figure represent relative necrotic area in tumor sections. In study I, all three control tumors at right showed no necrosis (0%). In
study II, photomicrographs of residual viable tumor and adjacent necrotic tumor tissue are shown at a higher magnification of 12.5x on the right.
A 40x magnification to show few layers of residual viable tumor cells is shown in the inset.
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When Hep3B tumors grew to approximately 2000 mm3,
tumor-bearing mice were euthanized. This study allowed
us to assess any delay of tumor growth in the treatment
group. The results, summarized in Figure 5B, indicated a
significant delay of tumor growth after one single infusion
of 10 μg MECA32-Fab-TF into a tumor feeding artery. The
average number of days after injection before tumors grew
to 1600 mm3 were 9.8 ± 3.0 days and 51.8 ± 3.2 days for the
control and treatment mice, respectively. The results of
these two studies indicate that infusion of anti-PLVAP
MECA32-Fab-TF into the tumor feeding artery istherapeutically effective for inducing tumor necrosis and
suppressing tumor growth.
Effect of systemic administration of anti-PLVAP
MECA32-Fab-TF on growth of Hep3B tumor xenografts
To determine whether the therapeutic effect of MECA32-
Fab-TF could be achieved through systemic administration,
we studied the effect of intravenous injection of 10 or
20 μg of MECA32-Fab-TF through a tail vein into a SCID
mouse bearing a Hep3B tumor xenograft. The control
group was injected with PBS buffer. Tumor volume was
monitored after treatment on day 0. The final tumor
Figure 5 Tumor growth after infusing MECA32-Fab-TF or control
MECA32 mAb into a tumor feeding artery. The results of two
different studies were shown here. In study A, tumor bearing mice
were treated with 5 or 10 μg MECA32-Fab-TF or 10 μg MECA32 mAb.
All mice were euthanized 24 days after treatment. The growth rates
between the treatment groups and the control group were compared
using a linear mixed-effects model. Significant differences in tumor
growth between controls and 5 μg or 10 μg treatment groups were
noted (p = 0.003 and 0.001). In study B, tumor bearing mice were
treated with 10 μg MECA32-Fab-TF (n = 4) or control MECA32 mAb
(n = 2). Mice were sacrificed when tumors grew large enough to
interfere with movement and food intake. The average numbers of
days required to reach a tumor size of 1600 mm3 for control and
treatment groups were 9.8 and 51.8 days, respectively. Different
rates of tumor growth were noted between experiments and
between mice within the same experiments. Therefore, effort was
made to match tumor sizes between control and treatment groups
in each study.
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lysis of variance and there were not significantly different
differences (p = 0.96). The average tumor volumes were
1844 ± 840 mm3 (control, n = 3), 1867 ± 602 mm3 (20 μg
MECA32-Fab-TF, n = 3) and 1617 ± 559 mm3 (10 μg
MECA32-Fab-TF, n = 3). Thus, infusion of MECA32-Fab-TF into a tumor feeding artery was necessary to achieve
the therapeutic effect.
Toxicity and pharmacokinetic studies of MECA32-Fab-TF
To determine the safety profile of MECA32-Fab-TF, we
administered 100 μg MECA32-Fab-TF through a tail
vein in each mouse. The amount injected was 10 times
of an upper therapeutic dose. In this study, four male
and four female 8-week-old mice were divided into four
groups. Each group consisted of 1 male and 1 female.
Before and after injection, mice were bled for complete
blood counts and plasma MECA32-Fab-TF concentra-
tion. Coagulation factor X and fibrinogen levels were
also measured to assess possible intravascular consump-
tion of these coagulation factors. Groups I, II, III, and IV
were bled at 30 seconds, 10 minutes, 30 minutes and
24 hours after injection, separately. Groups I and II were
bled again on day 4. Groups III and IV were bled on day
6. After treatment, the treated mice were closely moni-
tored for possible bleeding and body weight loss for
2 weeks. The result of our study showed a short circulation
half-life of 25 minutes for MECA32-Fab-TF. There was
transient reduction of plasma factor X to 30% of baseline
value at 30 minutes after injection. Platelet counts also
showed transient reduction at 30 minutes and were recov-
ered at 96 hours after injection. There was no significant
change of plasma fibrinogen level or body weight. These
results are summarized in Additional file 1: Figure S5.
Discussion
The use of TF to trigger thrombosis of tumor blood ves-
sels and induce tumor necrosis was reported by Huang
et al. [23]. The authors demonstrated that tumor cells
engineered to secrete gamma interferon induced expres-
sion of major histocompatibility complex (MHC) class II
antigens in tumor vascular endothelial cells. The induced
expression of class II MHC antigens can be used as targets
to treat tumor using bi-specific antibody against class II
MHC antigens and water-soluble form tissue factor. The
bi-specific antibody carried tissue factor to tumor blood
vessels and induced thrombosis. However, this approach
was applicable only to tumor cells engineered to secrete
gamma interferon. The lack of naturally occurring specific
targets in tumor vascular endothelial cells limits the ap-
plicability of such a therapeutic approach.
The high degree of differential expression of PLVAP we
identified in HCC vascular endothelial cells offered an
ideal target to test whether anti-PLVAP antibody coex-
pressing human tissue factor can be used to treat HCC.
Due to technical infeasibility to infuse our therapeutic bio-
logic into tumor feeding hepatic artery in mice, we estab-
lished a HCC xenograft model with blood supply from
femoral artery. in SCID mice. The results of our study
demonstrate that recombinant anti-PLVAP Fab-TF is able
Wang et al. BMC Cancer 2014, 14:815 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/815to achieve therapeutic effects as anticipated. In addition to
HCC, anti-PLVAP Fab-TF potentially may be used for the
treatment of malignant glioma. Similar to HCC, PLVAP
was highly expressed in vascular endothelial cells of gli-
oma, but not in vascular endothelial cells of normal brain
tissue [24].
In our study, the number of mice used in each experi-
ment was limited, because infusion of anti-PLVAP Fab-TF
into hair size tumor feeding femoral artery is technically
challenging and has precluded us from having a larger
number of mice in each experiement. Nevertheless, con-
sistent results were obtained in many different experi-
ments. We administered anti-PLVAP Fab-TF through a
tumor feeding artery out of concern of systemic toxicity. It
is known that PLVAP is expressed in many normal organs
and tissues, including the endocrine glands, digestive or-
gans, kidneys, lungs and others [25]. We reasoned that in-
fusion of anti-PLVAP Fab-TF into the tumor feeding
artery would provide a saturating concentration of anti-
PLVAP Fab for binding to the target antigen and reduce
the amount of Fab-TF required to achieve therapeutic ef-
fect through systemic administration. Despite the presence
of PLVAP in various normal organs and tissues, we did
not find any significant adverse effects after arterial infu-
sion. Histological examination of organs did not reveal
any pathology. The low systemic toxicity of anti-PLVAP
Fab-TF was further supported by our systemic administra-
tion of a high dose of anti-PLVAP Fab-TF through a tail
vein in mice (Additional file 1: Figure S5). The lack of
systemic toxicity was likely due to the short half-life of
Fab-TF, the dilution of anti-PLVAP Fab-TF in systemic
circulation, and the extensive presence of PLVAP in the
lungs and other organs. The amount of anti-PLVAP Fab-
TF that bound to the endothelial cells of normal organs
might be too low and quickly inactivated by tissue factor
pathway inhibitor.
After knowing that anti-PLVAP Fab-TF had little sys-
temic toxicity, we tested the therapeutic effects of anti-
PLVAP Fab-TF via systemic administration. However, we
were unable to achieve the same therapeutic effect when
administering anti-PLVAP-Fab-TF through a tail vein. The
lack of therapeutic effect via systemic administration may
have been due to an insufficient amount of anti-PLVAP-
Fab-TF reaching the tumor target for the same reasons that
systemic administration did not elicit any system toxicity.
Our study suggests that the therapeutic effects of anti-
PLVAP-Fab-TF for treatment of HCC best be achieved
through infusion into a tumor feeding artery similar to the
current TACE/TAE procedures.
Our finding that arterial infusion was necessary to
achieve therapeutic effect differs from an earlier study re-
ported by Huang et al. [23]. The authors of that study
showed that systemic intravenous injection of a bi-specific
antibody to class II MHC antigen and human TF hadinduced tumor necrosis. This discrepancy was likely due
to differential distributions of the targeted antigens. Ex-
pression of the class II MHC antigens used by Huang
et al. was exclusively restricted to tumor vascular endothe-
lial cells, and class II MHC antigens were not present in
the endothelial cells of normal organs or tissues. There-
fore, no class II MHC antigens in normal organs or tissues
to compete for binding of bi-specific antibody to tumor
vascular endothelial cells. The absence of competition
allowed the injected bi-specific antibody to be gradually
accumulated in tumor tissue. In our case, PLVAP was
present in many other non-hepatic organs, which may
prevent effective accumulation of TF in tumors when
anti-PLVAP Fab-TF was administered systemically. There-
fore, anti-PLVAP Fab-TF was not therapeutically effective
through systemic administration and required direct ad-
ministration into tumor feeding artery to achieve its thera-
peutic effect.
Histological examination of the treated tumors revealed
very small numbers of viable tumor cells remaining at the
tumor edge (Figure 4). This finding is not unexpected be-
cause tumor cells at the edges of HCC can receive collat-
eral blood supply from surrounding tissue making them
resistant to thrombotic blockage of tumor blood vessels.
To further prevent re-growth of the residual tumor cells
at the tumor edges, anti-angiogenic therapy after anti-
PLVAP Fab-TF treatment is an attractive option and war-
rants further study.
Current major approaches for treating intermediate stage
HCC rely mainly on transcatheter arterial injection of che-
moembolic agents or radiolabeled embolic spheres, local
ablation using radiofrequency heating and/or intra-tumoral
alcohol injection. The effectiveness of these approaches is
often limited by size, number, shape and anatomical loca-
tion of targeted tumors. There are also inherent limitations
to each of these therapeutic modalities. For instance, che-
moembolic agents and radiolabeled embolic spheres are
not HCC specific and can produce bystander cytotoxicity
[8-10]. It is also difficult to control the distribution of vis-
cous emulsion and embolic particles within tumors during
theses procedures. The shunting of therapeutic agents
from tumor blood vessels into normal liver and systemic
circulation can lead to unwanted complications. In cases of
advanced stage HCC, patients often have to rely on sys-
temic chemotherapy or targeted therapy (e.g. sorafenib).
Unfortunately, severely compromised liver function in
these patients often precludes them from receiving cyto-
toxic chemotherapy. Targeted therapy using sorafenib pro-
vides only a modest survival benefit to some patients [13].
The limitations and challenges of existing systemic treat-
ments and the development of new targeted systemic treat-
ment have been recently reviewed [26,27].
We believe limitations of different therapeutic modalities
mentioned above may be addressed by the use of anti-
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characteristics, high selectivity for HCC, and low systemic
toxicity. The low viscosity of anti-PLVAP Fab-TF without
any embolic particles may provide more even distribution
and potentially more complete blockage of tumor blood
flow. The low systemic toxicity of anti-PLVAP Fab-TF may
also allow us to treat patients with compromised liver
function and more advanced HCC.Conclusions
The results of our study show that there is a high degree
of differential expression of PLVAP between HCC and
adjacent non-tumorous liver tissue. This differential ex-
pression can be exploited to treat HCC with arterial in-
fusion of anti-PLVAP Fab-TF using procedures similar to
TACE as demonstrated in the proof of concept small
animal studies reported here. The potential advantages
of using anti-PLVAP Fab-TF to treat HCC include low
systemic toxicity and low viscosity. These advantages
may allow more HCC patients with advanced diseases
eligible for treatment. Further development of anti-
human PLVAP Fab-TF for trial in HCC patients is
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